Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.20M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.21M
EBITDA Margin
-271.50%
TTM Avg
-294.22%
3Y Avg
-453.19%
5Y Avg
-366.18%
Market Cap
$5.09M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$5.11M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
Market Cap
$5.01M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
Market Cap
$4.83M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.20M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.21M | -271.50% | -294.22% | -453.19% | -366.18% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.19M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.32M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.09M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| Imunon, Inc. (IMNN)vs › | $5.11M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | -8.85% | 9.13% | 18.32% | 18.32% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.83M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.54M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.73M | -1670.57% | -1446.66% | -2067.25% | -1679.39% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
